Immunoregulatory factors (IRF3 and IRF7) serum levels and its relation to disease activity in Vitiligo patients

Authors

  • Maha Anani Department of Clinical Pathology and Clinical Chemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Omayma Hassan Department of Dermatology and Venereology, ministry of health, Egypt
  • Fadia Attia Department of Clinical Pathology and Clinical Chemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Moustafa Eyada Department of Dermatology and Venereology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
  • Ghada Mohammed Department of Dermatology and Venereology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Keywords:

Vitiligo, Interferon gamma, IRF7, IRF3

Abstract

Background Occurrence of vitiligo was reported in patients treated with IFN (Interferons) for melanoma, hepatitis C, and hepatitis B. This suggests IFN and its immunoregulatory factors may play a role in the pathogenesis of vitiligo. However, the immunopathogenesis remains largely unknown.   Objective Explore the role of immunoregulatory factor 7 (IRF7) and immune-regulatory factor 3 (IRF3) in the serum of vitiligo patients.   Methods We studied (n=94) vitiligo patients and compared them with healthy control subjects. All included                subjects were submitted to full history taking, dermatological examination, VASI score calculation. IRF7 and IRF3 levels were assessed by IRF7 and IRF3 Immunoassay ELISA kit.   Results  Serum IRF-7 and IRF-3 are not elevated in vitiligo patients, and is associated with the least severity of the disease.   Conclusion Our data suggest that the serum levels of type 1 IFN (IRF7) and (IRF3) are not implicated in vitiligo pathogenesis. However, Age and duration of disease showed a negative correlation with IRF3 serum levels with statistically significant correlation.  

References

Ezzedine, K., et al., Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1-13.

Lin, J.Y. and D.E. Fisher, Melanocyte biology and skin pigmentation. Nature. 2007;445(7130):843-50.

Taieb, A. and M. Picardo, Clinical practice. Vitiligo. N Engl J Med. 2009;360(2):160-9.

Lili, Y., et al., Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One. 2012; 7(5):e37513.

McCully, M.L., et al., Epidermis instructs skin homing receptor expression in human T cells. Blood. 2012;120(23):4591-8.

van den Boorn, J.G., et al., Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol, 2009;129(9):2220-32.

Klarquist, J., et al., Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res. 2010;23(2):276-86.

Seif El Nasr, H., et al., Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. J Eur Acad Dermatol Venereol. 2013;27(1):103-8.

Hirobe, T., Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. Pigment Cell Res. 2005;18(1):2-12.

Harris, J.E., et al., A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869-76.

Peisley, A., et al., Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc Natl Acad Sci. 2011;108(52):21010-5.

Kawai, T., et al., IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 2005;6(10):981-8.

Chattopadhyay, S. and G.C. Sen, dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. J Interferon Cytokine Res. 2014; 34(6):427-36.

Sankar, S., et al., IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines. Cell Signal. 2006;18(7):982-93.

Rashighi, M., et al., CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23.

Yang, L., et al., Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo. Acta Derm Venereol. 2015;95(6):664-70.

Tamura, T., et al., The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26: 535-84.

Yanai, H., H. Negishi, and T. Taniguchi, The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology. 2012;1(8): 1376-86.

Eguchi, J., et al., Transcriptional control of adipose lipid handling by IRF4. Cell Metab. 2011;13(3):249-59.

Basak, P.Y., et al., The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009;60(2): 256-60.

Christensen, J.E., et al., Differential impact of interferon regulatory factor 7 in initiation of the type I interferon response in the lymphocytic choriomeningitis virus-infected central nervous system versus the periphery. J Virol. 2012;86(13):7384-92.

Dwivedi, M., et al., Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. J Interferon Cytokine Res. 2013;33(11):646-59.

Downloads

Published

2023-03-05

How to Cite

1.
Anani M, Hassan O, Attia F, Eyada M, Mohammed G. Immunoregulatory factors (IRF3 and IRF7) serum levels and its relation to disease activity in Vitiligo patients. J Pak Assoc Dermatol [Internet]. 2023Mar.5 [cited 2024Mar.29];33(1):137-41. Available from: http://www.jpad.com.pk/index.php/jpad/article/view/2053

Issue

Section

Original Articles